Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2005

View Archived Issues

Potent and selective CCR3 antagonist DPC-168 from BMS enters phase I

Antioxidants prevent doxorubicin-induced cardiotoxicity without altering anticancer effect

GABA-B antagonist exhibits antidepressant effects

Psoriasin, a newly discovered protein, protects human skin from E. coli infection

Gene transfer rapidly immunizes mice against anthrax

Safety data studied for Reminyl

Enrollment completed in phase III HARS study of Serostim

TURNS to test Org-24448 for enhancing cognition in schizophrenic patients

Pharmos receives milestone for Zylet launch

Helix BioMedix in antiinfectives collaboration with Smith & Nephew

Sorin completes enrollment in JUPITER II study of Janus Carbostent

Approval for phase I trial of AL-108 for Alzheimer's

France requests further information on Exanta for AF

BioTie inlicenses BKT-104

Canadian clearance for phase I trial of VP-025 for neuroinflammatory disease

Schering AG and Novartis enter oncology copromotion agreement for PTK/ZK

Sulfatides enhance platelet and platelet-leukocyte aggregation

Peregrine gains access to Merck KGaA's protein expression technology

Lead antibodies identified under SOA-002 project collaboration

Teikoku Hormone and Grelan make progress in merger

Yamanouchi presents novel series of antidiuretic compounds

Taisho scientists prepare and test agents for obesity

Kyowa Hakko discloses agents for diabetes and related complications

New compounds for lipoprotein disorders described in patent literature

Scientists at Kowa identify PPARalpha agonists for hyperlipidemia, atherosclerosis, etc.

MAP kinase inhibitors in early development at Ono

Insulin sensitizers described in a patent

Cardiac remodeling interrupted, reversed by sildenafil

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026